Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

Patrick Reimann; I-A Mavroeidi; Jonathan Burghofer; Hossein Taghizadeh; Gerald Webersinke; B. Doleschal; null et al.

doi:10.1007/s00262-024-03842-y

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

Patrick Reimann, I-A Mavroeidi, Jonathan Burghofer, Hossein Taghizadeh, Gerald Webersinke, B. Doleschal, et al.

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	251
Pages (from-to)	251
Number of pages	12
Journal	Cancer Immunology, Immunotherapy
Volume	73
Issue number	12
DOIs	https://doi.org/10.1007/s00262-024-03842-y
Publication status	Published - 03 Oct 2024

Fields of science

303 Health Sciences
304 Medical Biotechnology
305 Other Human Medicine, Health Sciences
301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00262-024-03842-y

Cite this

@article{7958356120374e2cad5463aeac1073c8,

title = "Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.",

author = "Patrick Reimann and I-A Mavroeidi and Jonathan Burghofer and Hossein Taghizadeh and Gerald Webersinke and B. Doleschal and {et al.}",

year = "2024",

month = oct,

day = "3",

doi = "10.1007/s00262-024-03842-y",

language = "English",

volume = "73",

pages = "251",

journal = "Cancer Immunology, Immunotherapy",

number = "12",

}

TY - JOUR

T1 - Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

AU - Reimann, Patrick

AU - Mavroeidi, I-A

AU - Burghofer, Jonathan

AU - Taghizadeh, Hossein

AU - Webersinke, Gerald

AU - Doleschal, B.

AU - et al., null

PY - 2024/10/3

Y1 - 2024/10/3

UR - https://pubmed.ncbi.nlm.nih.gov/39358611/

UR - http://www.scopus.com/inward/record.url?scp=85205526840&partnerID=8YFLogxK

U2 - 10.1007/s00262-024-03842-y

DO - 10.1007/s00262-024-03842-y

M3 - Article

C2 - 39358611

VL - 73

SP - 251

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 12

M1 - 251

ER -

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.

Fields of science

UN SDGs

Access to Document

Other files and links

Cite this